spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Dravet Syndrome 

 HSMN NewsFeed - 11 Feb 2020
Encoded Therapeutics Expands Gene Therapy Leadership with Key Appointment and Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Dec 2019
Encoded Therapeutics Strengthens Senior Leadership Team with Key Appointments in Regulatory and Human Resources Functions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Sep 2019
Encoded Therapeutics Expands Leadership Team with Key Appointments, Adding Expertise in Manufacturing and Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jul 2019
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 26 Jun 2019
Encoded Therapeutics, Inc. Announces $104 Million Series C Financing to Advance Lead Gene Therapy Program in Dravet Syndrome and Unveils its Precision Gene Therapy Platform
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 27 Jun 2018
Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Treatment of Autoimmune Hepatitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Dec 2017
GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex(R) (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 23 Aug 2017
Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of Patients With Dravet Syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 Apr 2017
Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 27 Jan 2017
Biscayne Announces Formation of Biscayne Neurotherapeutics and Completion of Series B Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 6 Jan 2017
Zogenix Announces CFO Transition
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 27 Jun 2016
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 May 2015
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Mar 2015
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Oct 2014
Zogenix Acquires U.K.-Based Brabant Pharma
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 2 Jul 2014
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Dravet Syndrome, a Rare Form of Epilepsy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 28 Feb 2014
GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome
Biopharmaceuticals FDA
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.